News | January 07, 2008

Brief Ischemia Episodes Create Cardioprotective Effect

January 7, 2008 - Ischemia experienced in brief episodes could protect the heart by preparing it for a heart attack, according to early findings from an animal study by researchers at the University of Cincinnati, which was published in the January issue of the American Journal of Physiology: Heart and Circulatory Physiology.

Rat hearts transfused with blood preconditioned by mini “stress tests” from reduced blood flow had significantly better reperfusion after heart attack-like ischemia than those that received a transfusion from donors that were not subjected to stress beforehand (P

Preconditioning activated a protective pathway called Janus kinase (JAK) to signal transducers and activators of transcription (STAT). The JAK-STAT pathway could offer a therapy against the damage of a heart attack.

A transfer of protection suggested that the effect was mediated by a soluble molecule released during brief periods of stress. Researchers indicated that this molecular mediator likely activates the JAK-STAT pathway.

Hearts that received effluent from preconditioned hearts but were treated with the JAK 2 inhibitor AG-490 recovered less than any other group.

Increased STAT-3 activation, reduced STAT-1 activation, and decreased expression of the pro-apoptotic protein Bax were associated with the protective effect.

Researchers do not yet know how long the cardioprotective effect lasts after a brief period of ischemia. However, "translating this phenomenon into a clinically useful tool may protect the myocardium from potential injury in a variety of settings," she said, "including acute myocardial infarction, cardiac revascularization surgery, supply/demand imbalance in congestive heart failure, and ischemia/reperfusion challenge following shock."

For more information: ajpheart.physiology.org


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now